<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004393</url>
  </required_header>
  <id_info>
    <org_study_id>199/12217</org_study_id>
    <secondary_id>YALESM-7764</secondary_id>
    <nct_id>NCT00004393</nct_id>
  </id_info>
  <brief_title>Phase II Double Blind Placebo Controlled Trial of Risperidone in Tourette Syndrome</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Office of Rare Diseases (ORD)</source>
  <brief_summary>
    <textblock>
      OBJECTIVES: I. Conduct a randomized, double blind, placebo controlled, parallel study of the&#xD;
      atypical neuroleptic risperidone (RIS) in the treatment of children and adults with moderate&#xD;
      to severe Tourette Syndrome.&#xD;
&#xD;
      II. Evaluate further the safety of RIS in this population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE: This is a randomized, double blind, placebo controlled study. Initially,&#xD;
      all patients receive placebo capsules twice daily in a single blind fashion during the first&#xD;
      2 weeks of study.&#xD;
&#xD;
      Then, patients are randomized to receive either risperidone (RIS) or placebo for 8 weeks. The&#xD;
      dose of RIS is increased weekly over the first 4 weeks of treatment, as tolerated.&#xD;
&#xD;
      Patients continue RIS for 4 additional weeks at the dose prescribed during week 4.&#xD;
&#xD;
      All patients receive diagnostic evaluations at the beginning and end of the 2 week initial&#xD;
      single blind phase, and at the end of weeks 2, 4, 6, and 8 of the active treatment phase.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 1997</start_date>
  <completion_date>September 2000</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>50</enrollment>
  <condition>Tourette Syndrome</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>risperidone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:&#xD;
&#xD;
        --Disease Characteristics--&#xD;
&#xD;
        DSM-IV diagnosis of Tourette Syndrome (TS)&#xD;
&#xD;
        Tic symptoms greater than 3 (moderate or worse) on the Global Clinical Impression Scale for&#xD;
        TS&#xD;
&#xD;
        --Prior/Concurrent Therapy--&#xD;
&#xD;
        No concurrent use of other medications during study&#xD;
&#xD;
        A minimum of 4 weeks since prior use of other medications and 8 weeks for neuroleptics or&#xD;
        fluoxetine&#xD;
&#xD;
        --Patient Characteristics--&#xD;
&#xD;
        Hepatic: No hepatic disease&#xD;
&#xD;
        Renal: No renal disease&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No heart disease&#xD;
&#xD;
          -  No hypertension&#xD;
&#xD;
        Pulmonary: No pulmonary disease&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  IQ at least 70 required&#xD;
&#xD;
          -  No other movement disorder allowed, such as tardive dyskinesia&#xD;
&#xD;
          -  No major depression&#xD;
&#xD;
          -  No pervasive developmental disorder&#xD;
&#xD;
          -  No autism or psychotic disorder based on DSM-IV&#xD;
&#xD;
          -  No alcohol or substance abuse&#xD;
&#xD;
          -  No hypersensitivity to risperidone&#xD;
&#xD;
          -  All subjects must be in good health&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bradley S. Peterson</last_name>
    <role>Study Chair</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <verification_date>March 2001</verification_date>
  <study_first_submitted>October 18, 1999</study_first_submitted>
  <study_first_submitted_qc>October 18, 1999</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 1999</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Tourette syndrome</keyword>
  <keyword>neurologic and psychiatric disorders</keyword>
  <keyword>rare disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tourette Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risperidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

